RS66041B1 - Derivati aminopiridina i njihova upotreba kao selektivnih alk-2 inhibitora - Google Patents

Derivati aminopiridina i njihova upotreba kao selektivnih alk-2 inhibitora

Info

Publication number
RS66041B1
RS66041B1 RS20241041A RSP20241041A RS66041B1 RS 66041 B1 RS66041 B1 RS 66041B1 RS 20241041 A RS20241041 A RS 20241041A RS P20241041 A RSP20241041 A RS P20241041A RS 66041 B1 RS66041 B1 RS 66041B1
Authority
RS
Serbia
Prior art keywords
amino
phenyl
nicotinamide
azabicyclo
hexan
Prior art date
Application number
RS20241041A
Other languages
English (en)
Serbian (sr)
Inventor
Jialiang Li
Luca Arista
Sreehari Babu
Jianwei Bian
Kai Cui
Michael Patrick Dillon
Rene Lattmann
Lv Liao
Rita Ramos
Nikolaus Johannes Stiefl
Thomas Ullrich
Peggy Usselmann
Xiaoyang Wang
Liladhar Murlidhar Waykole
Sven Weiler
Yubo Zhang
Yizong Zhou
Tingying Zhu
Dimitrios Lizos
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of RS66041B1 publication Critical patent/RS66041B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
RS20241041A 2016-07-20 2017-07-18 Derivati aminopiridina i njihova upotreba kao selektivnih alk-2 inhibitora RS66041B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662364620P 2016-07-20 2016-07-20
EP21202619.9A EP3971177B1 (en) 2016-07-20 2017-07-18 Aminopyridine derivatives and their use as selective alk-2 inhibitors

Publications (1)

Publication Number Publication Date
RS66041B1 true RS66041B1 (sr) 2024-11-29

Family

ID=60991950

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20241041A RS66041B1 (sr) 2016-07-20 2017-07-18 Derivati aminopiridina i njihova upotreba kao selektivnih alk-2 inhibitora
RS20211582A RS62819B1 (sr) 2016-07-20 2017-07-18 Derivati aminopiridina i njihova upotreba kao selektivnih alk-2 inhibitora

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20211582A RS62819B1 (sr) 2016-07-20 2017-07-18 Derivati aminopiridina i njihova upotreba kao selektivnih alk-2 inhibitora

Country Status (25)

Country Link
US (3) US10710980B2 (enExample)
EP (3) EP4442317A3 (enExample)
JP (4) JP7030776B2 (enExample)
KR (7) KR102719881B1 (enExample)
CN (2) CN109641871B (enExample)
AR (1) AR109108A1 (enExample)
AU (5) AU2017298187B2 (enExample)
CY (1) CY1124967T1 (enExample)
DK (2) DK3971177T3 (enExample)
EA (2) EA202190285A1 (enExample)
ES (2) ES2984746T3 (enExample)
FI (1) FI3971177T3 (enExample)
HR (2) HRP20241015T1 (enExample)
HU (2) HUE057328T2 (enExample)
LT (2) LT3487851T (enExample)
MX (2) MX388518B (enExample)
PL (2) PL3487851T3 (enExample)
PT (2) PT3971177T (enExample)
RS (2) RS66041B1 (enExample)
RU (1) RU2747318C2 (enExample)
SI (2) SI3487851T1 (enExample)
SM (2) SMT202400335T1 (enExample)
TW (5) TWI851226B (enExample)
UY (1) UY37331A (enExample)
WO (1) WO2018014829A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202190285A1 (ru) 2016-07-20 2021-08-31 Новартис Аг Производные аминопиридина и их применение в качестве селективных ингибиторов alk–2
PE20230251A1 (es) * 2019-11-22 2023-02-07 Incyte Corp Terapia de combinacion que comprende un inhibidor de alk2 y un inhibidor de jak2
CN111170893B (zh) * 2020-01-19 2022-04-26 郑州依米花手性药物研究有限公司 Lefamulin的中间体化合物及其在Lefamulin制备中的应用
TW202214239A (zh) * 2020-06-16 2022-04-16 美商英塞特公司 用於治療貧血之alk2抑制劑
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
WO2023198114A1 (zh) * 2022-04-13 2023-10-19 杭州邦顺制药有限公司 Alk2激酶抑制剂

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077290A (en) 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
NZ257631A (en) 1992-11-17 1996-03-26 Ludwig Inst Cancer Res Serine/threonine kinase domain-containing protein, dna and hosts therefor
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
US6914058B2 (en) * 2002-01-18 2005-07-05 Dr. Reddy's Laboratories, Limited Antibacterial compounds: process for their preparation and pharmaceutical compositions containing them
EP1501514B1 (en) 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
US20040067985A1 (en) 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
SE0203753D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
EP1623216A2 (en) 2003-04-11 2006-02-08 SGX Pharmaceuticals, Inc. Compound libraries and methods for drug discovery
AU2005247699A1 (en) 2004-05-27 2005-12-08 Pfizer Inc. Aminopyridine derivatives as selective dopamine D3 agonists
SA05260265A (ar) 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
EP1875912A4 (en) 2005-04-08 2008-06-04 Eisai R&D Man Co Ltd MEANS OF TREATING UNWILLING MOVEMENTS
WO2007011760A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
GB0517175D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
AR059036A1 (es) * 2006-01-17 2008-03-12 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
CA2649770C (en) 2006-04-18 2017-08-15 The Trustees Of The University Of Pennsylvania Mutated acvr1 for diagnosis and treatment of fibrodysplasia ossificans progressiva (fop)
WO2008002671A2 (en) 2006-06-29 2008-01-03 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors
CN101627055A (zh) 2006-09-05 2010-01-13 梅达雷克斯公司 骨形成蛋白及其受体的抗体以及它们的使用方法
JP2010503383A (ja) 2006-09-12 2010-02-04 ザ ジェネラル ホスピタル コーポレイション 細胞シグナリングをモジュレートする化合物を同定するための方法およびこのような化合物を使用する方法
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
US8507501B2 (en) 2008-03-13 2013-08-13 The Brigham And Women's Hospital, Inc. Inhibitors of the BMP signaling pathway
CN102203074A (zh) 2008-06-20 2011-09-28 麦它波莱克斯股份有限公司 芳基gpr119激动剂及其用途
RU2013104029A (ru) 2010-08-20 2014-09-27 ВАЙЕТ ЭлЭлСи Сконструированные остеогенные белки
CA2819955A1 (en) 2010-12-06 2012-06-14 Piramal Enterprises Limited Substituted imidazoquinoline derivatives
WO2012087938A1 (en) 2010-12-20 2012-06-28 Glaxosmithkline Llc Quinazolinone derivatives as antiviral agents
WO2012088438A1 (en) 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
BR112013029640A2 (pt) 2011-05-23 2017-06-13 Merck Patent Gmbh derivados de piridina e pirazina
DK2753605T3 (da) 2011-09-09 2019-06-17 Lantheus Medical Imaging Inc Sammensætninger, fremgangsmåder, og systemer til syntesen og anvendelsen af billeddannelsesmidler
AU2013324396B2 (en) * 2012-09-28 2018-10-04 Vanderbilt University Fused heterocyclic compounds as selective BMP inhibitors
US20160115167A1 (en) * 2013-03-04 2016-04-28 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
EP2970311A4 (en) 2013-03-14 2016-11-23 Brigham & Womens Hospital BMP HEMMER AND METHOD OF USE THEREOF
DK2970205T3 (da) * 2013-03-14 2019-07-29 Tolero Pharmaceuticals Inc JAK2- og ALK2-inhibitorer og fremgangsmåder til anvendelse deraf
RS59140B1 (sr) 2013-10-21 2019-09-30 Merck Patent Gmbh Heteroarilna jedinjenja kao inhibitori btk i njihova upotreba
US10260068B2 (en) 2014-03-31 2019-04-16 Sumitomo Dainippon Pharma Co., Ltd. Prophylactic agent and therapeutic agent for fibrodysplasia ossificans progressiva
WO2016118638A1 (en) 2015-01-20 2016-07-28 Merial Inc. Anthelmintic compounds, compositions and method of using thereof
PE20181017A1 (es) 2015-08-31 2018-06-26 Dong A Socio Holdings Co Ltd Compuestos heteroarilo y su uso como farmacos terapeuticos
EA202190285A1 (ru) * 2016-07-20 2021-08-31 Новартис Аг Производные аминопиридина и их применение в качестве селективных ингибиторов alk–2
US11462835B2 (en) 2016-07-20 2022-10-04 Qorvo Us, Inc. Method for tuning an antenna with a DVC
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation

Also Published As

Publication number Publication date
AU2024205058A1 (en) 2024-08-15
PL3971177T3 (pl) 2024-10-28
JP2025032086A (ja) 2025-03-11
RU2019104609A3 (enExample) 2020-09-30
PT3971177T (pt) 2024-07-30
TWI755255B (zh) 2022-02-11
AU2017298187A1 (en) 2018-12-20
WO2018014829A1 (en) 2018-01-25
SI3971177T1 (sl) 2024-10-30
ES2902521T3 (es) 2022-03-28
AR109108A1 (es) 2018-10-31
AU2021201424A1 (en) 2021-03-25
JP2022078137A (ja) 2022-05-24
CN109641871A (zh) 2019-04-16
CN114014844B (zh) 2024-10-01
EP4442317A3 (en) 2025-01-01
PT3487851T (pt) 2022-01-07
SMT202400335T1 (it) 2024-09-16
MX388518B (es) 2025-03-19
KR20240155367A (ko) 2024-10-28
US20190161474A1 (en) 2019-05-30
JP7253086B2 (ja) 2023-04-05
CN114014844A (zh) 2022-02-08
JP2023089012A (ja) 2023-06-27
KR20240074904A (ko) 2024-05-28
KR20190026917A (ko) 2019-03-13
HRP20211868T1 (hr) 2022-03-04
KR20220021023A (ko) 2022-02-21
TW201805277A (zh) 2018-02-16
JP2019521167A (ja) 2019-07-25
PL3487851T3 (pl) 2022-04-11
US10710980B2 (en) 2020-07-14
MX2021014852A (es) 2022-01-18
TWI712598B (zh) 2020-12-11
LT3487851T (lt) 2021-12-27
KR20220143770A (ko) 2022-10-25
AU2021201424B2 (en) 2022-10-20
TWI806385B (zh) 2023-06-21
KR20230117248A (ko) 2023-08-07
TW202336011A (zh) 2023-09-16
EP3487851A1 (en) 2019-05-29
TW202220969A (zh) 2022-06-01
FI3971177T3 (fi) 2024-07-30
RS62819B1 (sr) 2022-02-28
JP7030776B2 (ja) 2022-03-07
RU2021111037A3 (enExample) 2022-02-10
AU2019246857B2 (en) 2020-12-24
SI3487851T1 (sl) 2022-03-31
SMT202100723T1 (it) 2022-01-10
US20200299265A1 (en) 2020-09-24
EP3487851B1 (en) 2021-10-20
HUE067992T2 (hu) 2024-12-28
RU2021111037A (ru) 2021-05-13
CN109641871B (zh) 2021-10-22
EA202190285A1 (ru) 2021-08-31
MX2019000837A (es) 2019-07-04
CY1124967T1 (el) 2023-01-05
BR112019000941A2 (pt) 2019-04-30
KR102454129B1 (ko) 2022-10-14
KR102719881B1 (ko) 2024-10-23
US10947218B2 (en) 2021-03-16
HUE057328T2 (hu) 2022-05-28
RU2747318C2 (ru) 2021-05-04
EP4442317A2 (en) 2024-10-09
KR102667331B1 (ko) 2024-05-21
EP3971177B1 (en) 2024-06-26
AU2019246857A1 (en) 2019-10-31
ES2984746T3 (es) 2024-10-30
KR102281550B1 (ko) 2021-07-27
CA3030332A1 (en) 2018-01-25
HRP20241015T1 (hr) 2024-11-08
JP7584553B2 (ja) 2024-11-15
TW202134228A (zh) 2021-09-16
EP3487851A4 (en) 2019-12-25
DK3487851T3 (da) 2021-12-20
TW202509017A (zh) 2025-03-01
US12466808B2 (en) 2025-11-11
AU2023200265B2 (en) 2024-08-15
DK3971177T3 (da) 2024-07-15
UY37331A (es) 2018-02-28
EA037520B1 (ru) 2021-04-07
US20210155606A1 (en) 2021-05-27
AU2017298187B2 (en) 2019-11-14
AU2021201424C1 (en) 2023-02-02
RU2019104609A (ru) 2020-08-20
EA201990343A1 (ru) 2019-06-28
KR20210094138A (ko) 2021-07-28
KR102559539B1 (ko) 2023-07-26
KR102359707B1 (ko) 2022-02-09
TWI851226B (zh) 2024-08-01
AU2023200265A1 (en) 2023-02-16
EP3971177A1 (en) 2022-03-23
LT3971177T (lt) 2024-08-26

Similar Documents

Publication Publication Date Title
JP7584553B2 (ja) アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用
RU2826177C1 (ru) Производные аминопиридина и их применение в качестве селективных ингибиторов alk-2
HK40117528A (en) Aminopyridine derivatives and their use as selective alk-2 inhibitors
HK40069664B (en) Aminopyridine derivatives and their use as selective alk-2 inhibitors
HK40069664A (en) Aminopyridine derivatives and their use as selective alk-2 inhibitors
CA3030332C (en) Aminopyridine derivatives and their use as selective alk-2 inhibitors
HK40007022B (en) Aminopyridine derivatives and their use as selective alk-2 inhibitors
EA045493B1 (ru) Производные аминопиридина и их применение в качестве селективных ингибиторов alk–2
EA049492B1 (ru) Производные аминопиридина и их применение в качестве селективных ингибиторов alk–2